Table 3.
Anticancer activity as growth % in concentration 10−5 M for the compounds 5a, 5b, and 5d
| Compound | Mean growth% | Range of growth% | Most sensitive panel/cell line growth % |
|---|---|---|---|
| 5a | 71.26 | −84.63 to 124.07 | −84.63 Rc/UO-31, −77.98 M/MALME-3M, −69.53 NSCLc/NCI-H522, 3.17 Cc/HCC-2998, 8.46 Cc/HCC-116, 16.05 M/LOX IMVI, 19.57 L/CCRF-CEM, 26.33 L/SR, 33.32 Oc/OVCAR-3 |
| 5b | 86.17 | 5.19 to 136.81 | 5.19 NSCLc/NCI-H522, 21.51 L/SR,24.35 M/LOX IMVI, 29.34 Cc/HCT-116, 33.63 L/CCRF-CEM, 34.56 L/K-562, 47.57 Cc/SW-620 |
| 5d | 91.21 | −31.63 to 124.32 | −31.63 NSCLc/NCI-H522, 28.57 L/SR, 35.79 L/K-562, 40.46 Cc/HCT-116, 41.76 Rc/CAKI-1 |
Data obtained from the NCIs in vitro disease-oriented human tumor cells
L leukemia, NSCLc non-small cell lung cancer, Cc colon cancer, M melanoma, Oc ovarian cancer, Rc renal cancer